Pharming: FDA OKs Joenja® (leniolisib) as the first and only treatment indicated for APDS

 APDS (activated phosphoinositide 3-kinase delta (PI3Kδ) syndrome) is a rare and progressive primary immunodeficiency

Joenja® is a targeted treatment of APDS for adult and pediatric patients 12 years of age and older

Joenja® is expected to launch in the US in early April

Pharming will host a conference call for investors and analysts on March 27 at 14:00 CEST/08:00 EST

Investors and Analysts conference call dial-in information

March 27, 2023:  14:00CEST/08:00EST

Please note, the Company will only take questions from dial-in attendees.

Dial-in details:

Netherlands (Local)                 +31 85 888 7233

United Kingdom                      +44 808 189 0158

United Kingdom (Local)                       +44 20 3936 2999

United States                          +1 855 979 6654

United States (Local)                +1 646 664 1960

Global Dial-In Numbers

Access code: 040991

Webcast link: https://webcast.openbriefing.com/pharming-mar23/

https://finance.yahoo.com/news/pharming-announces-us-fda-approval-185100895.html